Select Page

High Speed Product Pipeline

We are currently developing several novel therapies and solutions for COVID 19

Rapid AI Development

Developing powerful therapies that kill COVID 19

Virologists Davey Smith MD MAS

World renowned virologists Davey Smith discuses the Linear Therapies antiviral compound.

An Innovative Biopharmaceutical Company Building a Diversified Pipeline of Revenue-Generating Pharmaceutical Products and Development-Stage Candidates

Linear Therapies is a company focused on the research & development of antimicrobial, anti-viral, and anti-cancer agents for the treatment of life-threatening diseases. Linear Therapies is using the breakthrough solubility technology to create new intellectual properties by formulating biologically active products into novel drugs with increased bioavailability. Linear Therapies is focusing on delivering a safe and immediate anti-pathogen specifically targeted at the COVID-19 pandemic. After accomplishing this primary objective, the company will expand the practice to address international threats including current and mutant-strains of SARS, MERS, Coronavirus, Ebola and natural and man-made threatening pathogens or bio-hazards.

Linear Therapies – A Chrono Brief

2020

January

Dr. Max Arella PhD, and Mr. Tim Yale meet in Europe to discuss Dr. Arella’s recently concluded and very successful RNA cancer therapy trials, in which pancreatic and ovarian cancers were fully arrested in the tested animals.  They surmise that the same process that produced such success with cancer-focused Custom-Targeted Molecules™ (CTM) can be adapted to fighting COVID-19. Dr. Arella accepts the challenge, and begins expanding his existing team and gathering additional experts.  

Within a week, Dr. Arella and his team begin employing a successful and previously approved RNA silencing technology that has been used in prior FDA approved therapies to directly target and kill the COVID-19 virus in humans. The science is based on RNA capping invented and patented by Dr. Yasuhiro Furuichi and lead by Dr. Max Arella. 

February 

Dr. Arella. Dennis Balzis, PhD, President of Solstar Pharma and Dr. Patrick Barnabe fly from Canada to Tokyo, Japan to meet with Dr. Furuichi to visit the Diamond Princess cruise ship – at that point, a floating quarantine hospital of COVID patients – and to design and prepare preliminary RNA sequences. Over twenty specific RNA sequences are identified and synthesized, and it’s agreed that the most aggressive COVID-19 outbreak is in Italy, and therefore makes the most sense as a location for live-testing. 

March 

Dr. Arella and Dr. Tien Canh take 6 of the 20+ antiviral sequences, or CTMs, to Italy to process invitro studies with the goal of identifying the most efficacious of them.  

April 

The Italian Government is made aware of the preliminary successful lab results and formally invites Dr. Arella and the team back to finalize the lab testing at the Italian Army laboratory in Rome. The new RNA sequences are synthesized with the modifications needed to treat the specific COVID-19 ravaging Italy. Compounds 309 and 313, the world’s first COVID-killing CTMs, are born of this process. 

May

Tim Yale returns to the US, and with the newly incorporated Linear Therapies begins assembling his American team to promote and process the US governments support and approval. Now with the joint-venture structured with Solstar Phama the intellectual property, existing patents and processes from the Canadian and Japanese teams are incorporated within Linear Therapies. 

July

Canada’s Western University tests Compound 309 against current U.S. standard therapeutic Remdesivir. Linear Therapies’ 309 shows a 7000 fold inhibition of the SARS-COVID-2 to Remdesivir’s 1.5 fold reduction. 

August

Application submitted for Biomedical Advanced Research and Development Agency (BARDA) financing of clinical trials.

Pre-Coronawatch meeting with BARDA, and affiliated partners throughout government.  Impressed by our invitro results, they encourage us to pursue animal trials, even offering NIH facilities to do so.

September

Linden Blue, Co-owner and Vice-Chairman of General Atomics, who is a world-renowned innovative visionary with more than a half-century of extreme impact in the sectors of aviation, space, defense, and energy, joins Linear’s board.

October

CTM Compound 309 defies industry expectations by achieving a 99.5% viral load reduction in its first round of animal trials at Scripps in La Jolla, CA. It represents a 6,000-fold increase over Remdesivir’s efficacy in animals. 

November

Linear finds a new American manufacturer, California-based Tri-Link, and establishes a partnership, initiating a complicated tech-transfer from Linear’s Japanese colleagues.

Dr. Davey Smith, head of the virology department of UCSD, and international protocol chair for the ACTIV-2 treatment study, which is a part of the US government’s Operation Warp Speed, joins Linear as chief science advisor.

December

Linear refines its CTM Compound 309 further, streamlining both its manufacturing processes and its delivery mechanism. CTM Compound 313 is born. 

2021

January

Linear expands partnerships with siRNA manufacturers, industry leaders in federal fast-track processing, labratory facilities and device experts in inhaled delivery for humans. These combined team members will insure the safe and effective delivery of the Linear antiviaral in the coming months.

February 

Linear has pre-clinical call with BARDA and assembled affiliates within the U.S. Government, in which they reiterate their enthusiasm for our COVID-killing CTMs, and advise us how to finish Phase I, so they can begin funding Phase II.

NEWS

Davey Smith, MD, MAS, Chief Science Advisor 1/6/21

Linear Therapies is pleased to announce the appointment of Davey Smith, MD, MAS, as Chief Science Advisor. During his career Davey has played an active roll fighting many diseases including HIV and COVID-19. Davey learned of Linear Therapies and their promising antiviral therapeutic when the molecule was first being tested at Scripps Laboratories in La Jolla. While he maintained mild skepticism from seeing many therapeutics fail in animal trials he agreed to observe and monitor the results. When the first trial produced a 99.4% viral load reduction, he saw a potential winner and agreed to join the Linear Therapies effort. His advice and cooperation to navigate the approval process has been extremely helpful accelerating the approval process with the goal of gaining emergency use authorization. 

Since the outbreak of SARS-CoV-2 in 2019, Dr. Smith has been actively engaged in the international effort to find safe and effective treatments. In particular, he is the international protocol chair for the ACTIV-2 treatment study, which is a part of the US government’s Operation Warp Speed. This study is designed to find effective therapies for persons with early COVID-19.

Davey is an infectious disease specialist focusing his effort on how to stop the transmission of HIV and curing HIV, and he has published over 200 scientific publications in these areas. In 2010, Dr. Smith was named HIV Researcher of the Year by the HIV Medical Association, and he became the co-director and principal investigator of the San Diego Center for AIDS Research (CFAR) in 2016.

Davey Smith, MD, MAS, Chief Science Advisor 1/6/21

Linear Therapies is pleased to announce the appointment of Davey Smith, MD, MAS, as Chief Science Advisor. During his career Davey has played an active roll fighting many diseases including HIV and COVID-19. Davey learned of Linear Therapies and their promising antiviral therapeutic when the molecule was first being tested at Scripps Laboratories in La Jolla. While he maintained mild skepticism from seeing many therapeutics fail in animal trials he agreed to observe and monitor the results. When the first trial produced a 99.4% viral load reduction, he saw a potential winner and agreed to join the Linear Therapies effort. His advice and cooperation to navigate the approval process has been extremely helpful accelerating the approval process with the goal of gaining emergency use authorization. 

Since the outbreak of SARS-CoV-2 in 2019, Dr. Smith has been actively engaged in the international effort to find safe and effective treatments. In particular, he is the international protocol chair for the ACTIV-2 treatment study, which is a part of the US government’s Operation Warp Speed. This study is designed to find effective therapies for persons with early COVID-19.

Davey is an infectious disease specialist focusing his effort on how to stop the transmission of HIV and curing HIV, and he has published over 200 scientific publications in these areas. In 2010, Dr. Smith was named HIV Researcher of the Year by the HIV Medical Association, and he became the co-director and principal investigator of the San Diego Center for AIDS Research (CFAR) in 2016.

Successful Animal Trials. 12/15/20

Linear Therapies is proud to announce that we have completed animal trials at Scripps Research Institute in La Jolla, CA related to our COVID-19 therapeutic. The successful results are forthcoming.

GSA APPROVED. 11/07/20

Linear Therapies is pleased to announce that we have been approved for products and services on the General Services Administration (GSA) contract. These products are listed under GSA contract number 47QTCA18D0089 and can be accessed and acquired via rapid acquisition using the GSA eBuy or other purchasing actions approved by the GSA.

Contact Us

Contact Us

12 + 10 =

Copyright 2021 Linear Therapies Inc.